4SC AG's Resminostat market size expected to increase many folds by 2032, report DelveInsight
DelveInsight has recently published a report on "Resminostat Market Forecast Report" providing an in-depth analysis of the Resminostat market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Resminostat market potential and market share analysis in the Cutaneous T-cell lymphoma therapeutics space across the 7MM from 2019 to 2032.The report also helps you to understand the Resminostat clinical and commercial developments along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.
Interested in finding out the projected market size of Resminostat by 2032? Visit: https://www.delveinsight.com/report-store/resminostat-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Resminostat Drug Summary
Resminostat is a potent inhibitor of class I, IIb, and IV HDACs, including a pronounced activity against HDAC6. In pharmacology studies, resminostat dose-dependently inhibited HDACs and induced acetylation of histone and non-histone proteins, resulting in changes in gene expression levels in tumor cells and the deregulation of pathways involved in cell differentiation, such as WNT signaling. Changes in cell differentiation are very often the cause of tumor progression, metastasis, and acquired resistance to anti-cancer treatment. Resminostat is currently being investigated in a pivotal study in cutaneous T-cell lymphoma (CTCL) as a maintenance treatment by 4SC in Europe and by Yakult Honsha in Japan.
Resminostat has demonstrated effects in CTCL-derived cell lines, stabilizing less advanced malignantly transformed T cells or even reversing advanced stages of disease to less advanced stages, which indicates a unique potential in both maintenance therapy as well as in the treatment of progressive disease.
In addition to these important effects on the differentiation of tumor cells, resminostat also increases the immunogenicity of tumors by enhancing natural killer (NK) cell recognition and killing, increasing expression and presentation of tumor-associated antigens (that support T-cell functions), and reducing unspecific immunosuppressive mechanisms.
In vivo, resminostat has demonstrated significant anti-tumor activity in various human xenograft mice tumor models, and in combination with established therapies-such as irinotecan or sorafenib - generated additive, synergistic anti-tumor effects.
In January 2023, 4SC AG announced that its pre-authorization eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T-cell lymphoma had been accepted.
Stay ahead of the competition by leveraging key insights and evolving trends in the Resminostat Market @ https://www.delveinsight.com/sample-request/resminostat-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Highlights of the Resminostat Market Report
The report contains forecasted sales evaluation of Resminostat for Cutaneous T-cell lymphoma till 2032.
It provides comprehensive coverage of late-stage emerging therapies for Cutaneous T-cell lymphoma treatment.
The report also features qualitative and quantitative analysis with analysts, as well as KOL views for Resminostat in Cutaneous T-cell lymphoma.
Why Resminostat Market Report?
Leading Resminostat for Cutaneous T-cell lymphoma forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Resminostat.
A thorough Resminostat market forecast will help understand how the drug is competing with other emerging therapies in the therapeutics landscape.
It will help to get an analysis of the Resminostat clinical trial advancements and the detailed clinical assessment, regulatory, and commercial assessment
The report also provides future market assessments for Resminostat market for Cutaneous T-cell lymphoma in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in Cutaneous T-cell lymphoma.
Download the sample report to learn more about the evolving market dynamics @ https://www.delveinsight.com/sample-request/resminostat-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Related Reports By DelveInsight:
Cutaneous T-cell lymphoma Market Outlook and Forecast
https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Cutaneous T-cell lymphoma Market Insights, Epidemiology and Market Forecast 2032" report delivers an in-depth understanding of Cutaneous T-cell lymphoma, historical and forecasted epidemiology as well as the Cutaneous T-cell lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the Cutaneous T-cell lymphoma therapeutics landscape.
Top Services Offered By DelveInsight:
Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting
Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment
Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard
Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential
428, Corporate Park, Sector-21, Dwarka,
New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 4SC AG's Resminostat market size expected to increase many folds by 2032, report DelveInsight here
News-ID: 3388720 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Resminostat
In Depth Research on Histone Deacetylase Inhibitors Market & Pipeline Insight201 …
"Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015" Report Highlights:
* Introduction & Classification Histone Deacetylase (HDAC) Inhibitors
* Mechanism of Histone Deacetylase (HDAC) Inhibitors
* Histone Deacetylase (HDAC) Inhibitors Market Dynamics
* Global Histone Deacetylase (HDAC) Inhibitor Market Outlook
* Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase
* Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline: 63
* Majority of Histone Deacetylase (HDAC) Inhibitor in Preclinical Phase: 35
* Marketed Histone Deacetylase…
Histone Deacetylase Inhibitors Market Sales Revenue Clinical Trials Pipeline Rep …
Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators…